Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
RENX.L - Renalytix PLC
Half Year 2025 Renalytix PLC Online Investor Presentation
Mar 18, 2025 / 02:00PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon everyone, thank you for joining the Renalytics presentation half year report. I'm joined by our CTO Fergus Fleming, and in the US, James McCulloch, the CEO of the company, is also online. For those of you who are new to this story, I don't know how many online are, Renalytics was formed out of a spin out of EKF. EKF in 2017 had two biomarkers called STNFR1 and STNFR2. Which would licensed out of Joslin Diabetes Institute in the United States, these biomarkers would show that if you're a diabetic, it would indicate whether you are likely to go on to get end stage renal disease or diabetic kidney disease.
Many years ago that would have been a so what test, but these days, this is a very valuable, these are
Trustpilot
